Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 2
2005 5
2006 5
2007 4
2008 5
2009 6
2010 10
2011 10
2012 13
2013 12
2014 12
2015 10
2016 6
2017 8
2018 8
2019 5
2020 7
2021 8
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
ER staining levels affect HER2 staining and heterogeneity.
Akashi M, Yamaguchi R, Kusano H, Yamaguchi M, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H. Akashi M, et al. Among authors: tanaka m. Breast Cancer. 2021 May;28(3):720-726. doi: 10.1007/s12282-020-01208-7. Epub 2021 Jan 9. Breast Cancer. 2021. PMID: 33423217
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Miyajima N, Ragab Eissa I, Abdelmoneim M, Naoe Y, Ichinose T, Matsumura S, Bustos-Villalobos I, Mukoyama N, Morimoto D, Shibata M, Takeuchi D, Tsunoda N, Kikumori T, Tanaka M, Kodera Y, Kasuya H. Miyajima N, et al. Among authors: tanaka m. Nagoya J Med Sci. 2021 Nov;83(4):683-696. doi: 10.18999/nagjms.83.4.683. Nagoya J Med Sci. 2021. PMID: 34916713 Free PMC article.
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment.
Eissa IR, Mukoyama N, Abdelmoneim M, Naoe Y, Matsumura S, Bustos-Villalobos I, Ichinose T, Miyajima N, Morimoto D, Tanaka M, Fujimoto Y, Sone M, Kodera Y, Kasuya H. Eissa IR, et al. Among authors: tanaka m. Int J Cancer. 2021 Jul 1;149(1):214-227. doi: 10.1002/ijc.33550. Epub 2021 Mar 23. Int J Cancer. 2021. PMID: 33687756 Free article.
123 results